Paper26190889
SGI-110: DNA Methyltransferase Inhibitor Oncolytic.
Griffiths EA and 5 others. Drugs Future, 2013. Cited by 57 papers, by iCite.
Cite this record
ConductScience Library. SGI-110: DNA Methyltransferase Inhibitor Oncolytic. Papers, record 26190889. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/26190889
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| R01 CA116674 | NCI NIH HHS | United States | R01CA116674 | PubMed and NIH |
Source NIH RePORTER
References34
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12011120 | Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. | J Clin Oncol | 2002 | https://conductscience.org/library/papers/12011120 | PubMed |
| 2 | 1606615 | Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. | Cell | 1992 | https://conductscience.org/library/papers/1606615 | PubMed |
| 3 | 11498573 | The role of DNA methylation in mammalian epigenetics. | Science | 2001 | https://conductscience.org/library/papers/11498573 | PubMed |
| 4 | 15215868 | Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. | Nature | 2004 | https://conductscience.org/library/papers/15215868 | PubMed |
| 5 | 16532500 | Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. | Cancer | 2006 | https://conductscience.org/library/papers/16532500 | PubMed |
| 6 | 17616700 | Delivery of 5-aza-2'-deoxycytidine to cells using oligodeoxynucleotides. | Cancer Res | 2007 | https://conductscience.org/library/papers/17616700 | PubMed |
| 7 | 10555141 | DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. | Cell | 1999 | https://conductscience.org/library/papers/10555141 | PubMed |
| 8 | 23519618 | A rapid and sensitive assay for DNA-protein covalent complexes in living cells. | Nucleic Acids Res | 2013 | https://conductscience.org/library/papers/23519618 | PubMed |
| 9 | 16413389 | A pharmacodynamic study of 5-azacytidine in the P39 cell line. | Exp Hematol | 2006 | https://conductscience.org/library/papers/16413389 | PubMed |
| 10 | 6208998 | Effect of uridine on response of 5-azacytidine-resistant human leukemic cells to inhibitors of de novo pyrimidine synthesis. | Cancer Res | 1984 | https://conductscience.org/library/papers/6208998 | PubMed |
| 11 | 17564707 | Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). | Cancer Chemother Pharmacol | 2008 | https://conductscience.org/library/papers/17564707 | PubMed |
| 12 | 23138873 | Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. | Cancer Immunol Immunother | 2013 | https://conductscience.org/library/papers/23138873 | PubMed |
| 13 | 19230772 | Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19230772 | PubMed |
| 14 | 2425959 | Phase I and pharmacokinetic study of 5-aza-2'-deoxycytidine (NSC 127716) in cancer patients. | Cancer Res | 1986 | https://conductscience.org/library/papers/2425959 | PubMed |
| 15 | 9260521 | Cytosine methylation and the ecology of intragenomic parasites. | Trends Genet | 1997 | https://conductscience.org/library/papers/9260521 | PubMed |
| 16 | 20564122 | A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. | Cancer | 2010 | https://conductscience.org/library/papers/20564122 | PubMed |
| 17 | 25316809 | The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25316809 | PubMed |
| 18 | 11257100 | Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. | Hum Mol Genet | 2001 | https://conductscience.org/library/papers/11257100 | PubMed |
| 19 | 6170748 | High-performance liquid chromatographic analysis of chemical stability of 5-aza-2'-deoxycytidine. | J Pharm Sci | 1981 | https://conductscience.org/library/papers/6170748 | PubMed |
| 20 | 6948829 | Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. | J Clin Invest | 1982 | https://conductscience.org/library/papers/6948829 | PubMed |
Cited by45
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 57 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42435177 | Epigenetic Targeting in Myeloid Malignancies. | Adv Exp Med Biol | 2026 | https://conductscience.org/library/papers/42435177 | PubMed |
| 42196535 | Recent Advances in Searching for DNMT Inhibitors and Their Potential Application in Treating Human Diseases. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42196535 | PubMed |
| 42194057 | Mechanism and Therapeutic Potential of Viral Mimicry in Cancer Immunotherapy. | Biomolecules | 2026 | https://conductscience.org/library/papers/42194057 | PubMed |
| 41987339 | DNMT3A in cancer: from epigenetic writer to oncogenic driver. | Clin Epigenetics | 2026 | https://conductscience.org/library/papers/41987339 | PubMed |
| 41673722 | Targeting epigenetic methylation: emerging diagnosis and therapeutic strategies in cancer. | Exp Hematol Oncol | 2026 | https://conductscience.org/library/papers/41673722 | PubMed |
| 40702903 | Guadecitabine improved relapse-free survival in high-risk acute myeloid leukemia and myelodysplastic syndrome patients after transplant: phase II results from a single center. | Haematologica | 2026 | https://conductscience.org/library/papers/40702903 | PubMed |
| 40641934 | The role of DNA methylation and demethylation in bladder cancer: a focus on therapeutic strategies. | Front Oncol | 2025 | https://conductscience.org/library/papers/40641934 | PubMed |
| 40025589 | Advances in epigenetic treatment of adult T-cell leukemia/lymphoma: a comprehensive review. | Clin Epigenetics | 2025 | https://conductscience.org/library/papers/40025589 | PubMed |
| 38231126 | Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. | Blood Adv | 2024 | https://conductscience.org/library/papers/38231126 | PubMed |
| 37489400 | Therapeutic Applications of Azanucleoside Analogs as DNA Demethylating Agents. | Epigenomes | 2023 | https://conductscience.org/library/papers/37489400 | PubMed |
| 37297025 | Resistance of Leukemia Cells to 5-Azacytidine: Different Responses to the Same Induction Protocol. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37297025 | PubMed |
| 37276510 | Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. | Blood Adv | 2023 | https://conductscience.org/library/papers/37276510 | PubMed |
| 37190176 | What's Next after Hypomethylating Agents Failure in Myeloid Neoplasms? A Rational Approach. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37190176 | PubMed |
| 37056286 | Role and mechanism of DNA methylation and its inhibitors in hepatic fibrosis. | Front Genet | 2023 | https://conductscience.org/library/papers/37056286 | PubMed |
| 36979633 | Epigenetic Regulators of DNA Cytosine Modification: Promising Targets for Cancer Therapy. | Biomedicines | 2023 | https://conductscience.org/library/papers/36979633 | PubMed |
| 36934257 | Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells. | J Exp Clin Cancer Res | 2023 | https://conductscience.org/library/papers/36934257 | PubMed |
| 36834962 | Solute Carrier Family 29A1 Mediates In Vitro Resistance to Azacitidine in Acute Myeloid Leukemia Cell Lines. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36834962 | PubMed |
| 36797244 | Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/36797244 | PubMed |
| 36707610 | LINE-1 ORF1p as a candidate biomarker in high grade serous ovarian carcinoma. | Sci Rep | 2023 | https://conductscience.org/library/papers/36707610 | PubMed |
| 36060265 | 5-methylcytosine turnover: Mechanisms and therapeutic implications in cancer. | Front Mol Biosci | 2022 | https://conductscience.org/library/papers/36060265 | PubMed |
Genes18
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/26190889
GET https://conductscience.org/api/papers/v1/26190889/references?page=2